×
BDMD dropped -13.33% to $0.0923 during Tuesday's regular session, falling from Monday's close of $0.1065; the decline was contained entirely within market hours. The slide followed proxy materials filed Monday after the close for a November 30 extraordinary general meeting, where holders vote on a 1-for-50 share consolidation, a dual-class structure giving Class B shares 100 votes each, and a repurchase of 18,195,281 Class A shares funded by issuing the same number of Class B shares.
SSII dropped -4.44% to $1.285 in Tuesday's regular session shortly before 10:00 a.m. ET, down from Monday's close of $1.35. The decline extends the reaction to third-quarter results published after Monday's close: revenue halved to $6.33 million from $12.83 million a year earlier, falling well short of the roughly $15 million consensus, while the net loss widened to $5.75 million.
CODX dropped from a $0.22 close to roughly $0.20, a -9.09% decline, all of it during Tuesday's regular session after shares opened lower and slid to an intraday low near $0.19. No verified news or fundamental catalyst found to explain the drop: the 9:05 a.m. ET release of a routine Peru dengue-test order and a MEDICA trade-show exhibit was too small and too positive to account for a -9% slide, so the move is likely continued liquidation in a thin order book, consistent with Monday's -13% session and a typical daily swing near 5.4%.
Both BSX and SYK are large medical technology companies, but their recent relative performance and market positioning have diverged sharply. BSX has declined roughly 53% year to date amid pressure on its WATCHMAN and electrophysiology (EP) franchises, while SYK has fallen a far more moderate 11%.
Edwards Lifesciences (EW) shares gained roughly 23.7% over the last 30 days, climbing from a close near $86.60 in mid-October to about $107.11. The advance was driven primarily by stronger-than-expected Q3 2026 results and a raised full-year outlook, reported on November 4, 2026.
The central $1.00 stock price target is the arithmetic mean of the current verified analyst price targets, which average roughly $1.03 and span a wide $0.60 to $1.50 range. With shares trading near $0.21 after a sharp post-earnings decline, reaching $1.00 would require a very large upside of roughly 376% .
Third-quarter 2026 revenue fell to $24.3 million , down from $33.3 million a year earlier and below the consensus estimate of roughly $26.3 million. The company reported a net loss of $3.6 million, or $0.03 per share , missing analyst expectations of a $0.02 per-share loss.
CapsoVision (CV) jumped +8.13%, or +$0.49, to $6.52 from Friday's close of $6.03, with the move taking place during Monday's regular session after a slightly firmer premarket quote. No verified news or fundamental catalyst found: no company release, SEC filing, analyst action or sector event dated to Monday explains the gain. The advance is likely a technical rebound after five straight lower closes that cut shares -15% from the October 28 close of $7.06, consistent with a micro-cap that averaged a 2.5% daily move over the past 60 sessions.
Pipeline catalysts matter most. CapsoVision's medium-term story centers on the commercial adoption of CapsoCam Colon and the in-development CapsoColon 3D platform, both targeting the large colorectal cancer screening opportunity. AI-enabled imaging is a differentiator. The company is positioning itself around advanced imaging and artificial intelligence (AI)-enabled capsule endoscopy, which could support faster reading times and improved polyp detection as software capabilities expand.
CODX dropped to $0.2332 in Monday's regular session, down -9.84% from Friday's close of $0.2586, with the decline occurring during market hours. The move extends selling that followed the Nov. 13 special meeting, where shareholders authorized reverse splits totaling up to 1-for-750 and approved share issuances for 3,404,724 warrants and secured convertible note conversions — heavy dilution for a company holding $0.71 million of cash.
Co-Diagnostics, Inc. (CODX) is a U.S.-listed molecular diagnostics company that develops tests based on the detection and analysis of nucleic acids (DNA or RNA). The company's flagship initiative is the Co-Dx PCR platform , a portable polymerase chain reaction (PCR) testing system designed for point-of-care and at-home use.
POAS is the NYSE American ticker for Phaos Technology Holdings (Cayman) Limited, a micro-cap developer and manufacturer of advanced optical and microscopy technologies. The company is headquartered in Singapore and was founded in 2017, operating through subsidiaries focused on research, development, manufacturing, and commercialization of optical products.
POAS dropped from a $3.29 close on Nov 13 to $2.755, a -16.11% decline during Monday's regular session, after already trading -9.88% lower in premarket. No verified news or fundamental catalyst found: there was no filing, press release or analyst action ahead of the move, so it is likely the unwinding of last week's speculative surge, when shares jumped +234.18% in one session and +9.30% the next without disclosure.
SSII is the Nasdaq ticker for SS Innovations International, Inc., a commercial-stage developer of surgical robotics technologies. The company's flagship product is the SSi Mantra surgical robotic system, supported by its SSi Mudra line of surgical instruments.
VNRX fell to $0.20 from Friday's close of $0.23, a -13.04% decline recorded during Monday's regular market session. No verified news or fundamental catalyst found for today's slide; it is most consistent with profit-taking after Friday's +24.66% earnings-driven spike, in a micro-cap that averages a 5.78% daily move and logged three swings larger than today's within the past 60 sessions.
VNRX is the stock ticker for VolitionRx Limited, a multinational epigenetics company developing simple, low-cost blood tests for cancer and diseases linked to NETosis, such as sepsis. The company's technology is built on its Nu.Q platform, which measures nucleosomes in blood as biomarkers of disease.
XTNT is the ticker for Xtant Medical Holdings, Inc., a U.S.-based medical technology company listed on the NYSE American exchange. The company designs, develops, manufactures, and markets orthobiologics and spinal implant systems used in spinal fusion and other orthopedic and neurological procedures.
Xtant Medical (XTNT) fell from $0.27 at Friday's close to $0.21, a -22.22% decline, with the drop occurring during Monday's regular session after an early premarket gain reversed. The move followed third-quarter 2026 results released before the open: revenue of $24.3 million missed the $26.3 million consensus, EPS of -$0.03 missed by a cent, full-year 2026 guidance was withdrawn, and the board announced a strategic review.
Microbot Medical Inc. ( MBOT ) is a U.S.-listed medical device company developing robotic technology for minimally invasive endovascular procedures. The company's flagship product is the LIBERTY Endovascular Robotic System , described by the company as the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
MBOT is at $0.60, down -38.78% from Friday's $0.98 close; the decline came in Monday's regular session, with shares gapping to $0.65 at the open and trading as low as $0.53. The catalyst is the third-quarter 2026 report: revenue fell to $72,000 from $241,000 in Q2, EPS came in at -$0.09, and gross margin turned negative on an $815,000 inventory write-down, signaling slower-than-expected LIBERTY adoption.